Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Dow Jones
2024-12-28
    Activities                          (5,000,000)              - 
                                       ------------   ------------ 
 
Cash Flows From Financing 
Activities: 
Proceeds from common stock option 
 exercises                                        -         31,267 
Merger, net                             (3,831,357) 
Net proceeds from registered direct 
 offerings                               13,803,684     13,798,183 
                                       ------------   ------------ 
   Net Cash Provided By Financing 
    Activities                            9,972,327     13,829,450 
                                       ------------   ------------ 
 
Net Change in Cash and Cash 
 Equivalents                           (23,229,048)   (15,230,762) 
Cash and Cash Equivalents -- 
 Beginning of Year                       26,480,928     41,711,690 
                                       ------------   ------------ 
Cash and Cash Equivalents -- End of 
 Year                                 $   3,251,880  $  26,480,928 
                                       ============   ============ 
 
Supplemental Disclosures of Cash 
Flow Information and Non-cash 
Activities: 
 
IPR&D Milestones included in License 
 Payable                              $  28,400,000  $           - 
Prepaid Manufacturing transferred to 
 Inventory                            $   6,134,895  $           - 
 
Reflects a 1-for-25 reverse stock split effective November 25, 2024. 
 

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-results-and-provides-business-update-302339718.html

SOURCE Citius Pharmaceuticals, Inc.

 

(END) Dow Jones Newswires

December 27, 2024 17:00 ET (22:00 GMT)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10